Investor Presentaiton

Investor Presentation First six months of 2018 Market access for the diabetes portfolio expected to be broadly unchanged in 2019 Current level of unrestricted market access for key Novo Nordisk diabetes products in the USA Slide 10 US formulary negotiations and 2019 pricing Formulary negotiations with pharmacy benefit managers and managed care organisations in the USA are progressing • Subject to final outcome of the negotiations, average prices after rebates are expected to be lower compared to 2018, predominantly due to basal insulin pricing and the changes to Medicare Part D coverage gap legislation • Market access is anticipated to remain broadly unchanged across the diabetes portfolio at a level similar to 2018 • Current market access for Ozempic® is above 60% for commercial and Part D combined Unrestricted Commercial Medicare part D • market access 100% 80% 60% 40% 20% 0% VictozaⓇ Levemir® TresibaⓇ NovoLogⓇ Source: FingerTip Formulary, May 2018 Note: Unrestricted access excludes prior authorisation, step edits and other restrictions changing diabetes novo nordisk

View entire presentation